Absci Corp
ABSI · XNASCIK 1672688fmd_1G374XS1RMFSYZ9YA33DHRYEZDServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 5 | 5 | 6 | 6 | 5 | 3 |
| Research and development | 11 | 45 | 59 | 48 | 64 | 81 |
| Selling, general and administrative | 6 | 29 | 41 | 38 | 36 | 35 |
| Total operating expenses | 18 | 80 | 112 | 121 | 113 | 123 |
| Operating income | (13) | (75) | (107) | (116) | (109) | (120) |
| Interest expense | 1 | 3 | 1 | 1 | 1 | 0 |
| Other non-operating income (expense) | (1) | (35) | 1 | 5 | 6 | 5 |
| Income before taxes | (14) | (110) | (105) | (110) | (103) | (115) |
| Income tax expense | 0 | (9) | (0) | 0 | 0 | 0 |
| Net income from continuing operations | (14) | (101) | (105) | (111) | (103) | (115) |
| Net income | (14) | (101) | (105) | (111) | (103) | (115) |
| Net income to common shareholders | (49) | (103) | (105) | (111) | – | – |